Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market

March 2002

Some patients with irritable bowel syndrome are begging the FDA to allow Lotronex (alosetron) back on the market.

Many patients benefited from Lotronex to control debilitating cramps and diarrhea. The problem is that sometimes it was TOO effective...causing severe constipation and ischemic colitis.

Now the FDA is trying to work out a limited access program...to make sure Lotronex is used only in appropriate patients.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote